Google Inc. (GOOG): FTC to Sue Over Patent Access Roadblocks

Google Inc. (NASDAQ:GOOG) bought Motorola Mobility earlier this year and has been strongly defending the company’s robust patent portfolio in the wireless and overall digital technology universe. Motorola has quite a few patents that are called “industry standard,” which means they are the patents that help the entire industry – specifically, for example, patents that allow all smartphones to interact with each other and between various wireless carriers. They are patents that help consumers communicate and thus there are supposed to be protections where holders of industry standard patents can be paid a licensing fee in exchange for competing companies to use those patents in a fair, reasonable and non-discriminatory (FRAND) manner.

Google Inc (GOOG)

But according to the Federal Trade Commission, Google Inc. (NASDAQ:GOOG) is not being very fair or reasonable in its dealings with competitors regarding these types of patents, and the group is due to file an antitrust lawsuit against Google Inc. (NASDAQ:GOOG), perhaps by the end of the year. FTC staff made the recommendation to sue to the entire board of commissioners, and it appears that the majority of the commission is in favor of the recommendation, which was evidenced by an earlier post here where we noted that the FTC had hired an antitrust expert, who is pretty much only hired to give testimony in legal proceedings.

Google Inc. (NASDQ:GOOG) has been investigated on its crusade to impose import bans on Microsoft Corporation (NASDAQ:MSFT) and Apple Inc. (NASDAQ:AAPL) products that infringe on industry-standard patents which Motorola Mobility owns. The investigation began this summer when the FTC sought information about whether Google Inc. (NASDAQ:GOOG) was offering licenses for technology that allowed Microsoft Corporation (MSFT) and Apple Inc. (AAPL) to use Motorola’s patents for 3G wireless, wi-fi and video streaming.

Can Google Inc. (NASDAQ:GOOG) overcome this issue? Should investors like billionaire fund manager David Tepper of Appaloosa Management LP be concerned about thi, or is this just “politics” that may go away after the election?

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!